TABLE 4.
Comparison of death and intubation rates among groups with advanced fibrosis
| Group | Survivors n = 174 | Nonsurvivors n = 185 | p value |
|---|---|---|---|
| Controla | 27 (15.52) | 16 (8.65) | <0.001* |
| Control and AFabc | 10 (5.75) | 7 (3.71) | |
| NAFLDa | 32 (18.39) | 22 (11.89) | |
| NAFLD and AFbc | 6 (3.45) | 19(10.27) | |
| MAFLDab | 81 (46.55) | 72 (38.92) | |
| MAFLD and AFc | 18 (10.34) | 49 (26.49) |
| Nonintubated n = 218 | Intubated n = 141 | p value | |
|---|---|---|---|
| Controla | 36 (16.5) | 7 (4.96) | 0.004 |
| Control and AFabc | 13 (5.5) | 5 (3.55) | |
| NAFLDabc | 33 (15.14) | 21 (14.89) | |
| NAFLD and AFabc | 14 (6.42) | 11 (7.8) | |
| MAFLDbc | 92 (42.2) | 61 (43.26) | |
| MAFLD and AFc | 31 (14.22) | 36 (25.53) |
Abbreviations: AF, advanced fibrosis; MAFLD, metabolic dysfunction‐associated fatty liver disease; NAFLD, nonalcoholic fatty liver disease.
a–cDifferent supercript letters indicate differences between groups (Bonferroni‐adjusted p < 0.0033).
*
Significant using Fisher´s exact test.